by ADRIAN MANZ | Aug 19, 2025 | The Doctor's Dose
Oracle’s AI Rally Pauses: A Deeper Dive with Day-Trading Setups Oracle (ORCL) slipped more than 4% to ~238 after a torrid June–July run that peaked at 260.87. Price is now decisively below the 21-day moving average while still hovering a few percent above the 50-day,...
by ADRIAN MANZ | Aug 19, 2025 | The Doctor's Dose
Merck Keytruda Medicare Delay: What It Means for Day Traders The recent tweak to Medicare’s drug price negotiation program has given Merck (MRK) a brief lifeline. While long-term investors are debating whether the change truly softens the looming Keytruda patent...
by ADRIAN MANZ | Aug 19, 2025 | The Doctor's Dose
A Tweak to Medicare is Good for Merck. But Can It Revive the Stock? Merck & Co. has found a small reprieve in Washington, but investors remain skeptical that it will meaningfully alter the company’s trajectory. A new tweak to Medicare’s drug price negotiation...
by ADRIAN MANZ | Aug 19, 2025 | The Doctor's Dose
September Fed Rate Cut: Why Day Traders Should Prepare for a Hawkish Surprise Fed expectations vs. market reality The S&P 500, currently hovering above 6400, has rallied on expectations of a September Fed rate cut. Fed funds futures are pricing an 85% chance of a...
by ADRIAN MANZ | Aug 18, 2025 | The Doctor's Dose
Intel Government Stake Talks and Day Trading Implications The Trump administration is reportedly considering a 10% equity stake in Intel (INTC), which would convert billions in CHIPS Act funding into ownership. The proposal underscores Washington’s deepening...
by ADRIAN MANZ | Aug 18, 2025 | The Doctor's Dose
Retail Earnings, Tariffs, and Day Trading: Where the Real Risk Lies Why this week matters Headline numbers may look fine; the risk is guidance as retailers speak to the back half (B2S and holiday). Tariff pass-through is the swing factor: modest so far, but price...
by ADRIAN MANZ | Aug 18, 2025 | The Doctor's Dose
Novo Nordisk Wegovy MASH approval: Why NVO is jumping—and how day traders can trade it Quick take Novo Nordisk shares pop after the FDA grants accelerated approval for Wegovy to treat MASH (metabolic dysfunction-associated steatohepatitis) with liver fibrosis in...
by ADRIAN MANZ | Aug 18, 2025 | The Doctor's Dose
DeepSeek’s AI Model Delay and the Impact on Intraday Trading Opportunities China’s AI Ambitions Face Technical Headwinds The delay in the DeepSeek AI model underscores a significant challenge in Beijing’s push to reduce reliance on U.S. technology. The Chinese AI...
by ADRIAN MANZ | Aug 17, 2025 | The Doctor's Dose
Weight-Loss Drug Stocks and Day Trading Opportunities Pharma’s Former Darling Turns Volatile The meteoric rise of weight-loss drug stocks such as Novo Nordisk and Eli Lilly was once seen as a safe haven in the pharmaceutical sector. Fueled by the popularity of GLP-1...
by ADRIAN MANZ | Aug 15, 2025 | The Doctor's Dose
Big Tech AI Talent War: How Reverse Acquihires Could Reshape Silicon Valley The Big Tech AI talent war is pushing Microsoft, Meta, Google and others to pursue a new playbook—poach founders and core researchers, license the IP, and leave the startup shell behind. It’s...
